{"id":7700,"date":"2020-11-05T11:31:13","date_gmt":"2020-11-05T11:31:13","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=7700"},"modified":"2020-11-05T11:31:13","modified_gmt":"2020-11-05T11:31:13","slug":"patients-with-a-rare-bowel-cancer-could-benefit-from-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/patients-with-a-rare-bowel-cancer-could-benefit-from-immunotherapy\/7700\/","title":{"rendered":"Patients with a rare bowel cancer could benefit from immunotherapy"},"content":{"rendered":"
Around 1% of patients suffering from bowel cancer experience colorectal peritoneal metastasis. This means that the cancer has spread to the lining of their abdomen, known as the peritoneal cavity.<\/p>\n
This type of spread in bowel cancer patients carries a very poor prognosis and most patients do not survive beyond 12 months from diagnosis. Conventional chemotherapy is ineffective, and current treatment consists of extensive surgery, which is not always successful.<\/p>\n
In a new study, funded by the Good Hope Hospital Charity, researchers from the University of Birmingham analysed the specific tumour biology of patients suffering from colorectal peritoneal metastasis.<\/p>\n